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While early stage prostate cancer (PCa) can be cured with surgery, metastatic disease is currently incurable. 
The prostate is a non-essential organ for life making gene-directed enzyme prodrug therapy (GDEPT) a 
feasible option. GDEPT involves the transfer of a non-mammalian prodrug converting enzyme into the 
tumour microenvironment. This enzyme renders the prostate tumour sensitive to killing by a systemically 
administered non-toxic prodrug following its conversion to a toxin. GDEPT shows several advantages: 
prodrug activation in the tumour avoids systemic toxicity; the toxic metabolite readily diffuses across cell 
membranes killing ‘local bystander’ PCa cells that do not express the prodrug converting enzyme; stimulation 
of anti-PCa immune cells providing PCa metastases killing (‘distant bystander effect’).  
 
We are currently exploring two GDEPT delivery methods for the treatment of metastatic PCa. The first 
method utilises the intratumoural injection of a sheep atadenovirus to deliver the bacterial purine nucleoside 
phosphorylase gene (PNP) under the control of a prostate targeting promoter and in the presence of prodrug 
fludarabine phosphate (FP253; PCTAU03/00381). FP253 has been registered for a first-in-man Australian 
Phase I clinical trial (http://ClinicalTrials.gov/NCT00625430). We are now successfully engineering bone 
marrow-derived mesenchymal stem cells (BMSC) to deliver the yeast cytosine deaminase uracil 
phosphoribosyltransferase fusion gene (CDUPRT) to metastatic PCa in the presence of prodrug 5-
fluorocytosine. BMSC have attracted much attention as cellular gene delivery vehicles due to their ability to: 
seek out cancer anywhere in the body; overcome issues of host immune responses allowing for allogeneic as 
well as autologous transplantation; avoid degradation by the immune system, a major limitation of most 
current gene delivery methods.  These novel GDEPT delivery methods show promise for the development of 
novel therapeutics for PCa patients presenting with metastatic disease. 
 
 
